[1]
|
杨森, 谢颂平, 黄杰. 可手术切除的局部进展期非小细胞肺癌患者新辅助治疗研究进展[J]. 实用心脑肺血管病杂志, 2022, 30(3): 131-136.
|
[2]
|
汪程, 胡剑鹏, 张骥, 徐伟, 陈师. 胸腔镜微创术与传统开胸术治疗非小细胞肺癌的对比分析[J]. 中国卫生标准管理, 2021, 12(18): 34-37.
|
[3]
|
丁国强, 白舒, 刘鸿运, 张大勇, 袁井贺. 单孔与三孔胸腔镜在早期肺癌手术治疗中的对比观察及对恢复时间的影响[J]. 航空航天医学杂志, 2019, 30(8): 948-949.
|
[4]
|
马长辉, 周悦, 刘锦源. 单孔胸腔镜手术治疗早期肺癌临床研究[J]. 中国临床研究, 2020, 33(1): 59-61+65.
https://doi.org/10.13429/j.cnki.cjcr.2020.01.013
|
[5]
|
李德刚. 胸腔镜肺癌手术与传统开胸手术在治疗老年非小细胞肺癌的临床指标对比[J]. 系统医学, 2020, 5(4): 73-75+84. https://doi.org/10.19368/j.cnki.2096-1782.2020.04.073
|
[6]
|
NSCLC Meta-Analysis Collaborative Group (2014) Preoperative Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Participant Data. The Lancet, 383, 1561-1571.
https://doi.org/10.1016/S0140-6736(13)62159-5
|
[7]
|
邹灵俊, 陈洪波, 郭晓康, 孙健, 张燕, 张德贤, 郭洪波. 非小细胞肺癌新辅助化疗联合手术预后影响因素分析[J]. 中华肿瘤防治杂志, 2022, 29(3): 179-185.
|
[8]
|
沈国刚, 李志杰, 陈羽彪. 探究术前新辅助化疗联合外科手术治疗非小细胞肺癌的临床效果[J]. 中国实用医药, 2020, 15(16): 45-47. https://doi.org/10.14163/j.cnki.11-5547/r.2020.16.017
|
[9]
|
丁江华, 龚升平. 多西紫杉醇及参一胶囊节拍疗法治疗老年进展期非小细胞肺癌[J]. 临床误诊误治, 2010, 23(1): 59-61.
|
[10]
|
Nagasaka, M. and Gadg-eel, S.M. (2018) Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. Expert Re-view of Anticancer Therapy, 18, 63-70. https://doi.org/10.1080/14737140.2018.1409624
|
[11]
|
Yoneda, K., Imanishi, N., Ichiki, Y. and Tanaka, F. (2019) Treatment of Non-Small Cell Lung Cancer with EGFR-Mutations. Journal of UOEH, 41, 153-163. https://doi.org/10.7888/juoeh.41.153
|
[12]
|
Yang, J.C.-H., Ahn, M.-J., Kim, D.-W., Ramalin-gam, S.S., Sequist, L.V., Su, W.-C., et al. (2017) Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 35, 1288-1296. https://doi.org/10.1200/JCO.2016.70.3223
|
[13]
|
Lazzari, C., Gregorc, V., Karachaliou, N., Rosell, R. and Santarpia, M. (2020) Mechanisms of Resistance to Osimertinib. The Journal of Thoracic Disease, 12, 2851-2858. https://doi.org/10.21037/jtd.2019.08.30
|
[14]
|
Xie, L., Nagpal, S., Wakelee, H.A., Li, G., Soltys, S.G. and Neal, J.W. (2019) Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. Oncologist, 24, 836-843.
https://doi.org/10.1634/theoncologist.2018-0264
|
[15]
|
Chen, R., Manochakian, R., James, L., Azzouqa, A.G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K. and Lou, Y. (2020) Emerging Therapeutic Agents for Advanced Non-Small Cell Lung Cancer. Journal of Hematology & Oncology, 13, 58. https://doi.org/10.1186/s13045-020-00881-7
|
[16]
|
Rijavec, E., Indini, A., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F. and Grossi, F. (2021s) Nivolumab plus Ipilimumab for the First-Line Treatment of Metastatic NSCLC. Expert Review of Anticancer Therapy, 21, 705-713.
https://doi.org/10.1080/14737140.2021.1903322
|
[17]
|
宋丽君, 马雪娇, 郑佳彬, 王学谦, 张英, 刘杰, 侯炜, 林丽珠, 蒋益兰, 解英, 李平, 王沈玉, 张洪亮, 舒琦瑾, 林洪生. 中医综合方案联合化疗治疗IV期非小细胞肺癌的多中心随机对照研究[J]. 北京中医药, 2022, 41(1): 2-6.
https://doi.org/10.16025/j.1674-1307.2022.01.001
|
[18]
|
Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. https://doi.org/10.1016/j.csbj.2019.03.006
|
[19]
|
Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Personal-ized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. https://doi.org/10.1038/s41591-021-01450-2
|
[20]
|
Dal Maso, A., Lorenzi, M., Ferro, A., et al. (2021) Real-World Data on Treatment Outcomes in EGFR-Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology, 17, 2513-2527. https://doi.org/10.2217/fon-2021-0356
|